Abstract:
BACKGROUND:The purpose of our cooperative trial was to investigate whether epirubicin (EPI) at 90 mg/m2 in a CHOP-like combination (called CEOP) could increase complete response (CR) and survival rates in non-Hodgkin lymphoma (NHL) patients while maintaining a tolerable degree of toxicity. METHODS:Between September 1986 and July 1992, 218 patients from 12 Centers in Lombardy entered this study. The inclusion criteria were: a histological diagnosis of intermediate or diffuse large cell (DLC) NHL and no previous radio-chemotherapy. The patients in stages IA and IIA (both intermediate and DLC) received four CEOP courses followed by local/regional radiotherapy; those with intermediate NHL in stages IB, IIB, III A and B and IV A and B received six CEOP courses and, if they achieved CR, three further courses as consolidation. RESULTS:Among the 160 evaluable patients, CR was observed in 90% of the subjects with DLC-NHL (stages IA and IIA) and in 59% of those with intermediate-grade NHL (all clinical stages). If the clinical stages are considered separately, the CR rates were 92% for stages IA, IIA and 53% for stages IB, IIB, III A and B, IV A and B. Relapses occurred in 20% of the patients treated with four CEOP courses plus radiotherapy and in 31% of those who received nine CEOP courses because of the advanced stage of their disease. As of May 1994, the median follow-up was 42 months. If all of the patients are considered together, the 7-year overall survival (OS) probability was 64% and the 7-year disease-free survival (DFS) probability 67%. In comparison with stages III/IV, the patients in stages I-II had better DFS (7-year chance 77% vs 56%, p < 0.03). Hematological toxicity was acceptable, and a delay in the administration of CEOP chemotherapy was required in only three patients. No life-threatening infections were recorded. CONCLUSIONS:Our cooperative study of the use of the CEOP combination in NHL patients shows that response rates and the length of DFS are equal to the best results obtained with CHOP and more intensive programs, although further confirmation must be provided by means of a longer follow-up and a more careful analysis of prognostic factors according to the recently proposed international index. In our experience, an EPI dose of 90 mg/m2 has negligible toxicity (particularly on bone marrow), even in elderly patients. These findings are interesting since it is well known that myelotoxicity is the principal limiting factor for the majority of anthracycline-containing regimens used in the treatment of potentially curable NHL.
journal_name
Haematologicajournal_title
Haematologicaauthors
Lambertenghi Deliliers G,Butti C,Baldini L,Ceriani A,Lombardi F,Luoni M,Montalbetti L,Pavia G,Pinotti G,Pogliani Esubject
Has Abstract,Author List Incompletepub_date
1995-07-01 00:00:00pages
318-24issue
4eissn
0390-6078issn
1592-8721journal_volume
80pub_type
临床试验,杂志文章,多中心研究相关文献
HAEMATOLOGICA文献大全abstract::The classification of myelodysplastic syndromes is based on the morphological criteria proposed by the French-American-British (FAB) and World Health Organization (WHO) groups. Accurate enumeration of blast cells, although essential for diagnosis of myelodysplastic syndrome and for assignment to prognostic groups, is ...
journal_title:Haematologica
pub_type: 共识发展会议,杂志文章
doi:10.3324/haematol.13405
更新日期:2008-11-01 00:00:00
abstract::Aplastic anemia is usually treated with immunosuppression or allogeneic transplant, depending on patient and disease characteristics. Syngeneic transplant offers a rare treatment opportunity with minimal transplant-related mortality, and offers an insight into disease mechanisms. We present here a retrospective analys...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.091074
更新日期:2013-11-01 00:00:00
abstract::Not available. ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2020.266320
更新日期:2021-01-28 00:00:00
abstract:BACKGROUND:The clonal origin of myeloproliferative disorders has been clearly demonstrated and it is known that reactive thrombocytosis occurs as a non specific response to various inflammatory or neoplastic conditions. Only a few papers have discussed the topic of myeloproliferative diseases in blood donors. MATERIAL...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1994-03-01 00:00:00
abstract::Circulating stem cells (CSC) are well documented in animals and humans. Though their function in normal conditions remains obscure, autologous CSC seem capable of restoring hemopoiesis after myeloablative treatment. With cell separators CSC may be harvested in adequate number, and collection may be further improved gi...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:
更新日期:1990-11-01 00:00:00
abstract::Translocation t(9;14)(p13;q32) involving PAX5 and IGH genes was first described in lymphoplasmacytic lymphoma. New data suggest that this translocation is not restricted to a specific morphologic subtype but occurs in other B-cell lymphomas. We present three cases with a diagnosis of splenic marginal zone lymphoma and...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2006-09-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:A magnetic resonance (MR) signal shows an inverse correlation with bone marrow cellularity. In this study, we investigated the possibility of estimating the degree of bone marrow cellularity by means of this non-invasive technique. METHODS:In 25 patients with different hematological disorders ...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1997-03-01 00:00:00
abstract:BACKGROUND:In recent years many therapeutic regimens have been designed in order to improve response rate and response duration in non-Hodgkin's lymphoma (NHL). In 1991 the Italian Lymphoma Study Group (GISL) started a prospective randomized trial on treatment of aggressive and advanced NHL, focused on the efficacy of ...
journal_title:Haematologica
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1993-09-01 00:00:00
abstract::Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy. For patients with relapsed/refractory multiple myeloma, we developed a treatment schema of metronomically scheduled drug therapy. We identified 186 patients who had been treated with metronomic therapy between March 2004 and...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.085183
更新日期:2013-07-01 00:00:00
abstract::Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatment insensitivity to FLT3 inhibitors, including sorafenib. Using a geno...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2020.257964
更新日期:2020-12-30 00:00:00
abstract:BACKGROUND:The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2011.056101
更新日期:2012-04-01 00:00:00
abstract:BACKGROUND:Chronic lymphocytic leukemia has a variable clinical course. Genomic aberrations identify prognostic subgroups, pointing towards distinct underlying biological mechanisms that are poorly understood. In particular it remains unclear whether the prognostic subgroups of chronic lymphocytic leukemia are characte...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.025734
更新日期:2010-11-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:A phase II study was conducted to investigate the effects of a therapeutic program based on the combination of fludarabine and cytarabine (ARA-C) administered as a sequential continuous infusion in untreated elderly patients with acute myeloid leukemia (AML). DESIGN AND METHODS:Sixty-three pa...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2005-06-01 00:00:00
abstract::Our objective was to determine whether the goal of high-dose therapy should be a partial hematologic response or a complete response. We analyzed 282 consecutive stem cell transplant patients. A partial hematologic response was achieved in 108 patients (38%), and 93 (33%) achieved a complete hematologic response. Surv...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.11413
更新日期:2007-10-01 00:00:00
abstract::Successful expansion of hematopoietic stem cells would benefit the use of hematopoietic stem cell transplants in the clinic. Several angiopoietin-like proteins, including angiopoietin-like 7, can support the activity of hematopoietic stem cells. However, effects of ANGPTL7 on human hematopoietic stem cells and the dow...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2014.118612
更新日期:2015-05-01 00:00:00
abstract::Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected. Chronic graft-versus-host disease is an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. This a...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.13311
更新日期:2008-11-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:The threshold for prophylactic platelet transfusions has been classically established at 20,000/microL. In 48 patients with de novo acute myeloblastic leukemia (AML) we analyzed the effect of reducing the threshold for prophylactic platelet transfusion from 20,000/microL (group A) to 10,000/mic...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1998-11-01 00:00:00
abstract::We report on a patient affected by multicentric Castleman's disease who developed an acute immunohemolytic anemia due to warm antibody. The clinical course was characterized by refractoriness to the steroidal treatment and by a dramatic improvement of the hematological and objective picture following combination chemo...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1996-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Recent progress in the development of diagnostic techniques has greatly facilitated the monitoring of minimal residual disease (MRD) in patients with chronic myeloid leukemia (CML) after allogeneic bone marrow transplantation (BMT), the only curative treatment for this disease. The presence of...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:
更新日期:2000-10-01 00:00:00
abstract::We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patie...
journal_title:Haematologica
pub_type: 信件
doi:10.3324/haematol.11155
更新日期:2007-09-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Subgroups of T-cell acute lymphoblastic leukemia (T-ALL), defined according to recurrent cytogenetic aberrations, may have different prognoses. The aim of this study was to determine the prognostic relevance of molecular-cytogenetic abnormalities in pediatric patients using quantitative real-t...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2006-09-01 00:00:00
abstract::Lactadherin is a phosphatidylserine-binding glycoprotein secreted by macrophages. Less than 0.5% of normal circulating red cells showed any binding to lactadherin. However, the red cells from patients with sickle cell disease showed 2 to 10-fold increases in lactadherin binding. Further, lactadherin stimulated the pha...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2005-09-01 00:00:00
abstract::Patients with hypogammaglobulinemia who do not fulfill all the classical diagnostic criteria for common variable immunodeficiency (reduction of two immunoglobulin isotypes and a reduced response to vaccination) constitute a diagnostic and therapeutic dilemma, because information concerning the clinical and immunologic...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.085076
更新日期:2013-10-01 00:00:00
abstract::The detection of iron deficiency anemia is challenged by the paucity of diagnostic tests demonstrating high sensitivity and specificity. Using two biomarkers, zinc-protoporphyrin/heme and hepcidin, we established the diagnostic cut-off values for iron deficiency anemia in preschool children and women. We randomly sele...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2018.193243
更新日期:2018-12-01 00:00:00
abstract::Hereditary spherocytosis (HS) originates from defective anchoring of the cytoskeletal network to the transmembrane protein complexes of the red blood cell (RBC). Red cells in HS are characterized by membrane instability and reduced deformability and there is marked heterogeneity in disease severity among patients. To ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2018.188151
更新日期:2020-01-31 00:00:00
abstract::Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared with placebo (COMFORT-I) and best available therapy (COMFORT-II). We pre...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3324/haematol.2014.119545
更新日期:2015-09-01 00:00:00
abstract::We investigated the presence of a recombinant event between the F8A gene located in intron 22 of the factor VIII gene and the two additional copies of F8A lying 500 Kb upstream of FVIII in severe hemophilic patients. The genomic DNA of 146 unrelated Italian patients with severe hemophilia A (HA) was hybridized with an...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1997-01-01 00:00:00
abstract::Rituximab has improved response rates and overall survival in B-cell lymphoma (DLBCL). Radiotherapy is an effective treatment modality for lymphomas, but there is uncertainty on its use as consolidation after chemo-immunotherapy mainly in advanced stages. We evaluated its efficacy with a comprehensive meta-analysis an...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2020.249680
更新日期:2020-06-18 00:00:00
abstract::In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytogenetic data of 302 p...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.026658
更新日期:2011-02-01 00:00:00
abstract::The aim of this study was to identify new pathogenic variations of the UGT1A1 gene in 11 patients diagnosed with neonatal unconjugated hyperbilirubinemia. We describe two cases in which clinically unapparent heterozygotic mutations in the UGT1A1 gene may become evident in combination with certain environmental conditi...
journal_title:Haematologica
pub_type: 信件
doi:10.3324/haematol.10585
更新日期:2007-01-01 00:00:00